The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis.
about
Brodalumab for the Treatment of Psoriasis: A Review of Phase III TrialsComparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-AnalysisThe Role of IL-17 and TH17 Cells in the Bone Catabolic Activity of PTHRole and Function of A2A and A₃ Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis.Circulating concentrations of interleukin (IL)-17 in patients with multiple sclerosis: Evaluation of the effects of gender, treatment, disease patterns and IL-23 receptor gene polymorphismsIL-17A Is Increased in Humans with Primary Hyperparathyroidism and Mediates PTH-Induced Bone Loss in MiceIL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patientsIncreased Circulating Th17 Cells, Serum IL-17A, and IL-23 in Takayasu ArteritisRole of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review).Biologic treatment in Sjögren's syndrome.The Human Leukocyte Antigen (HLA)-B27 Peptidome in Vivo, in Spondyloarthritis-susceptible HLA-B27 Transgenic Rats and the Effect of Erap1 Deletion.IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear.Biologics in spondyloarthritis: TNFα inhibitors and other agents.Macrophage Polarization and Bone Formation: A review.The role of the unfolded protein response in axial spondyloarthritis.Secukinumab (AIN-457) for the treatment of Psoriasis.New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.Secukinumab (AIN457) in the treatment of ankylosing spondylitis.Pathogenesis of ligaments ossification in spondyloarthritis: insights and doubts.Autoinflammation and HLA-B27: Beyond Antigen Presentation.Biologic Therapy for HLA-B27-associated Ocular Disorders.Cytokine profiles in axial spondyloarthritis.Clinical and Imaging Signs of Spondyloarthritis in First-Degree Relatives of HLA-B27-Positive Ankylosing Spondylitis Patients: The Pre-Spondyloarthritis (Pre-SpA) Cohort Study.IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis.Altered Immune Activation and IL-23 Signaling in Response to Candida albicans in Autoimmune Polyendocrine Syndrome Type 1Patient Burden of Axial Spondyloarthritis.IL-23R and IL-17A polymorphisms correlate with susceptibility of ankylosing spondylitis in a Southwest Chinese population.IL-17A Produced by Innate Lymphoid Cells Is Essential for Intestinal Ischemia-Reperfusion Injury.Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides.Mesenchymal stem cells provide novel insights into ankylosing spondylitis.It Takes “Guts” to Cause Joint Inflammation: Role of Innate-Like T Cells.The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis
P2860
Q26746100-729B3440-451A-46DA-A8D5-37C5BAA76A21Q26764820-E36FA9BB-56A9-4A21-97E2-BF080E164F0DQ26765844-DCB1CDC8-8579-4F11-A817-FAF365EA7066Q33624267-571B74B4-03F3-4755-B094-A037411925D9Q33896806-FAC056F6-86F7-4C8B-9C1A-2277016E0D6FQ36253707-FF60C0A4-C78F-4E79-96E5-970271FC6F33Q36611562-BAAE887F-3B79-4D47-B695-A3F0BB5D1CB1Q36731105-E87F4EDE-F29C-4670-B063-7090E4631288Q37720215-2EA4B12D-F16A-47D1-9AFC-00500F0CA479Q38262453-69A0D2EC-BC8D-46AF-BFBE-974215FF586DQ38380973-2B36953D-CCFF-4CDB-A9F4-6931B64B6078Q38421287-06C992F3-C39A-4782-B56A-2BE59949BD50Q38522331-6404BE1F-15B1-460B-BB0E-CD5865859608Q38615856-B89E2881-0C63-4AA5-A20E-A4F6A7E79B1BQ38633365-432B8693-74BF-45A6-BE28-93B41ECC8975Q38662868-F91D2694-9EFC-4E7F-82EE-F9F556F608EBQ38768900-BC8CC5E7-475D-4B48-8C41-3DE6CD7BD456Q38777116-FD5C0066-172F-4776-8DE9-045F357B8C4CQ38816459-0F7153A0-8F3F-412A-97D7-075752950C45Q38845301-95F9C20C-20E5-4B4A-AC6B-59906057C460Q38982632-27B7DD01-96F6-4D0D-9EBC-17623AD5D41BQ39608151-216F748E-4A4A-44A0-A8FE-8FB816B574FEQ40741048-020ECA42-5F06-4ED8-9761-6AA10F44E84EQ41353840-FF88D225-8709-4682-963B-4DD1E2E23E64Q41619568-F1AEB9B6-6230-4423-BFC2-4000B562FB18Q42365374-4BBB42B9-B692-4EF9-849E-13F5A29BF250Q42378430-1255801A-8A2D-432D-9FF3-AA78C444CBF7Q47846733-C4F7E8DF-AC99-4734-B3C2-6DD27C6826ECQ48332071-ED13782F-7EEC-44AA-9311-2101916FBBB1Q52843674-508AD014-31D2-4779-AE98-9A9C307DA04BQ55645985-8FBEC3AB-38F7-4C21-8D81-F5943BAF8CB8Q58761666-CF7820E4-18B3-4330-8C98-BEEDC1445706
P2860
The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The interleukin-23/interleukin ...... reatment of spondyloarthritis.
@en
type
label
The interleukin-23/interleukin ...... reatment of spondyloarthritis.
@en
prefLabel
The interleukin-23/interleukin ...... reatment of spondyloarthritis.
@en
P2093
P1476
The interleukin-23/interleukin ...... reatment of spondyloarthritis.
@en
P2093
Dominique Baeten
Jacqueline E Paramarta
Nataliya Yeremenko
P304
P356
10.1097/BOR.0000000000000069
P577
2014-07-01T00:00:00Z